© 2017 by BMR Solutions. 

Overview

Overview

According to the World Health Organization - Cancer is among the leading causes of death worldwide. In 2012, there were 14 million new cases and 8.2 million cancer-related deaths worldwide. Within the next two decades the number of new cancer cases will rise to 22 million. The American national cancer institute estimates that in 2016 - 1,685,210 new cases of cancer diagnosed in the United States and 595,690 people died from the disease, approximately 39.6 percent of all men and women (which is 1 out of every 3 women and 1 out of every 2 men) will be diagnosed with cancer at some point during their lifetimes. Most people that diagnosed with cancer receive chemotherapy and/or radiation therapy or a combination of both. These therapies are toxic.  A common dose limiting toxic effect is bone marrow suppression. Damage to the bone marrow harms its ability to create blood components and causes an immediate lethal danger because of deterioration of the immune system. All these disable the body's ability to deal with bacteria, viruses and/or fungi which naturally exist in human body and its surrounding.  

The fact that during past several decades cancer mortality steadily increases worldwide indicates the great need for novel revolutionary approach to cancer supportive care that offered by Bone Marrow Recovery Solutions ("BMR Solutions"). Current standard of care, based on transplantation of stem cells and therapeutics related to G-CSF, Erythropoietin and Thrombopoietin, are not sufficient according to morbidity and mortality rates.

 

BMR solutions’ game changing approach increases supply of the bone marrow stem cells from patient’s own body according to personal body needs. This leads for faster recovery of the whole blood parameters, white blood cells, red blood cells and platelets, and as a result, to substantial increase in survival rates and enhanced overall recovery.

 

THE COMPANY
The Company

BMR Solutions is a privately held Israeli biopharmaceutical company with a pipeline of small molecule drugs in late pre-clinical stages, addressing chemotherapy and irradiation associated hematological disorders. BMR Solutions is developing its most advanced drug candidate as a supportive care for cancer patients with impaired bone marrow and abnormal blood counts, as those who undergo chemotherapy  and/or irradiation treatments.